An FDA advisory panel has voted to back Bristol-Myers Squibb's belatacept, a new therapy designed to prevent the rejection of new kidney transplants. The experts voted 13 to 5 in favor of recommending ...
Despite some concerns over serious adverse events and long-term efficacy, members cited the need for alternatives. FDA’s advisory panel voted 13 to 5 to recommend Bristol-Myers Squibb’s Belatacept for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results